BackDr Reddy’s Laboratories launches cerebral stroke drug
The drug was an important product in the management of stroke and had been used for the treatment of post-stroke patients around the world
Premium
Hyderabad: Dr Reddy’s Laboratories Ltd (DRL) on Friday said it had launched cerebral stroke management drug Somazina in the Indian market. The drug is the innovator brand of Citicoline. DRL brought the drug to India in partnership with Ferrer Internacional SA of Spain.
The drug was an important product in the management of stroke and had been used for the treatment of post-stroke patients around the world, the company said in a statement. “With the launch of Somazina and our recent acquisition of Nootropil, through the UCB brands’ acquisition, we look forward to building our presence in the neurology segment," said Alok Sonig, senior vice-president and head of India business at DRL.
About 1.5 million people suffer strokes in India every year. Cerebral stroke is the third leading cause of deaths in India, as per the Global Burden of Disease Study 2013.
Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!
